By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and ...

On August 25, 2025, Valneva announced that the FDA suspended the license for its chikungunya vaccine, IXCHIQ®, in the U.S. due to four new reports of serious adverse events. This suspension requires ...

Those with private health insurance expected to have an easier time getting vaccines than those on Medi-Cal if CDC changes ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

The U.S. FDA has suspended the license for Valneva’s chikungunya vaccine Ixchiq after reports of severe side effects, ...